Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1116]
News [2426]
Articles [145]
Editorials [8]
Conferences [101]
elearning [11]
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )
30 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
Comment: Enfortumab vedotin is an effective therapy and important development...
Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak
Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )
18 Jun 2019
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo...
Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )
13 Jun 2019
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
13 Jun 2019
NILE: Should we give everything to patients with unresectable locally advanced...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer? ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
13 Jun 2019
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant...
Prof Thomas Flaig - University of Colorado Denver, Denver, USA
SWOG 1314: A study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for muscle-invasive bladder cancer ( Prof Thomas Flaig - University of Colorado Denver, Denver, USA )
10 Jun 2019
Genetic testing and PARP inhibitors in metastatic prostate cancer
Dr Neal Shore and Dr Joaquin Mateo
Genetic testing and PARP inhibitors in metastatic prostate cancer ( Dr Neal Shore and Dr Joaquin Mateo )
7 Jun 2019
Metastatic castration resistant prostate cancer: Updates from ASCO 2019
Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi
Metastatic castration resistant prostate cancer: Updates from ASCO 2019 ( Dr Neal Shore, Dr Joaquin Mateo and Prof Karim Fizazi )
7 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation